PTPRO and cancer: Moreover, the expression of PD-L1 in tumor cells is largely supported by the activation of EGFR, MAPK, PI3K/Akt or Jak/Stat3 pathways (70), some of which are found to be restrained by PTPRO in several cancer types (33, 40, 71).